Stock Option Plan - The stock option plan allows the company to grant rights to subscribe for up to 15,954,685 shares, representing approximately 9.30% of the issued shares as of the date of the 2024 annual report[3]. - As of June 30, 2024, a total of 8,958,290 stock options have lapsed, with no options granted, exercised, or cancelled during the fiscal year ending June 30, 2024[3]. - The number of stock options available for grant under the plan as of July 1, 2023, and June 30, 2024, is 6,996,395 and 15,954,685, respectively[3]. - The stock option plan is effective for a period of 10 years from the adoption date, unless otherwise cancelled or amended[3]. - No stock options were granted to connected persons or service providers that exceeded 0.1% of the relevant class of issued shares during any 12-month period as of July 1, 2023, and June 30, 2024[5]. - Any stock options granted must be approved by shareholders at a general meeting[4]. - The total value of stock options granted to connected persons must not exceed HKD 5,000,000 based on the closing price of shares on the grant date[4]. - The company emphasizes the importance of shareholder approval for any stock option grants to ensure compliance with listing rules[4]. Governance and Oversight - The company’s board of directors includes executive and independent non-executive directors, ensuring governance and oversight[7]. - The information in this announcement does not affect other data contained in the 2024 annual report[6].
玮俊生物科技(00660) - 2025 - 年度业绩